# L-Methylfolate

> L-Methylfolate (5-MTHF, levomefolic acid) is the terminal bioactive metabolite of folate and the only folate form that crosses the blood-brain barrier. It is neither a drug in the conventional sense…

Canonical: https://wiki.soapbox.community/wiki/L-Methylfolate
Section: Substances and pharmacology
Last updated: 2026-10-20
Publisher: Library of Ashurbanipal (Van Kush Family Research Institute), https://wiki.soapbox.community

**L-Methylfolate** (5-MTHF, levomefolic acid) is the terminal bioactive metabolite of folate and **the only folate form that crosses the blood-brain barrier**. It is neither a drug in the conventional sense nor an ordinary dietary supplement: it is the endpoint of a conversion pathway that a large minority of the population cannot complete efficiently.

The Institute's paper on it — *L-Methylfolate as a Trimonoamine Modulator*, first published 18 September 2021 on Blurt as @punicwax, expanded February 2026 — is the source for this article.

## Mechanism: the BH4 salvage pathway

Dietary folate and supplemental folic acid must be enzymatically reduced to become active. The final, rate-limiting step is catalysed by **MTHFR** (methylenetetrahydrofolate reductase), converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. **This conversion is irreversible, and a polymorphism reducing MTHFR activity creates a bottleneck that cannot be bypassed by taking more folic acid.** That is the entire clinical significance of the molecule in one sentence.

Downstream, L-methylfolate sustains the recycling of **tetrahydrobiopterin (BH4)**, the rate-limiting cofactor for three hydroxylases:

{| class="wikitable"
! Enzyme !! Substrate !! Product !! Neurotransmitter
|-
| Tryptophan hydroxylase || L-tryptophan || 5-HTP || Serotonin
|-
| Tyrosine hydroxylase || L-tyrosine || L-DOPA || Dopamine → noradrenaline → adrenaline
|-
| Phenylalanine hydroxylase || L-phenylalanine || L-tyrosine || feeds the above
|}

All three monoamine systems depend on the same cofactor, and that cofactor's regeneration depends on this folate. Hence **trimonoamine modulator**: one molecule upstream of all three.

## MTHFR polymorphisms

Two variants are clinically significant, **C677T** and **A1298C**. C677T heterozygotes show roughly **35% reduced** enzyme activity; homozygotes roughly **70% reduced**.

Prevalence of the T/T genotype is about **10% in Caucasian populations and 22% in Hispanic and Mediterranean populations** — including those of Phoenician and North African ancestry. The clinical consequence is direct: a patient with an MTHFR polymorphism prescribed an SSRI may respond poorly **not because the drug is wrong but because they lack the BH4 to synthesise the serotonin the SSRI recirculates**.

## Clinical evidence

- **Papakostas et al. (2012)** — two multicentre sequential-parallel trials in SSRI-resistant major depression. **15 mg/day** adjunctive L-methylfolate was significantly better than placebo; **7.5 mg/day was not**, establishing a dose-response. Post hoc, the largest responses were in patients with BMI ≥ 30 and elevated inflammatory markers (IL-8, IL-12, TNF-α, hsCRP, leptin).
- **Shelton et al. (2013)** — significant PHQ-9 improvement in naturalistic settings, including patients symptomatic for over two years.
- **Al Maruf et al. (2022)** — PRISMA-compliant meta-analysis; modest but significant adjunctive efficacy. NNT in biomarker-positive patients between 1 and 4.
- A **2025** open-label study found even 800 mcg alongside an antidepressant produced earlier improvement and higher remission than monotherapy.
- **NCT06218030**, a Phase 4 trial in treatment-resistant generalised anxiety disorder, is recruiting.

## Safety

The published profile is unusually clean: no known drug interactions, no reports of manic induction, none of the metabolic effects that accompany atypical-antipsychotic augmentation.

**The one real caution: assess B12 before starting.** Folate can mask the anaemia of B12 deficiency while the neurological damage of that deficiency continues unchecked. This is the standard folate caution and it applies here in full.

## The Amplification Framework

The paper situates L-methylfolate in a three-part model — **substrate provider**, **cofactor amplifier**, **degradation inhibitor** — arrived at by noticing that it occupies the same structural position for monoamines that piracetam occupies in the established cholinergic stack. See The Amplification Framework.

See also: The Amplification Framework · Racetams · Choline Donors · Stack Substances